Latest News and Press Releases

För mer information, vänligen kontakta:Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com ...

Director of Pharmaceutical R&D, Stefan Grudén, has been invited to present at the Annual Formulation and Drug Delivery Congress being held in London on 29-30 April. This annual congress is an...

Redeye has today released an updated research report on LIDDS covering its expanded portfolio that now also includes a project targeting Toll-like Receptors (TLR). The updated research report...

Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma på Virdings Allé 32B i Uppsala torsdagen den 16 maj 2019 kl. 15:00. Rätt att delta och anmälan Rätt att delta i...

Clinical data shows that intratumoral delivery of TLR agonists in combination with immune checkpoint inhibitors can effectively treat solid cancers. NanoZolid® technology is very suitable to provide...

The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid® technology patent. This will provide additional patent protection for all LIDDS development...

STOCKHOLM - LIDDS (Nasdaq First North: LIDDS) announced today that the company will evaluate a possible listing of its shares on Nasdaq Stockholm's Main Market during 2020 and will engage advisors...

The first patient has now been enrolled in the Phase I NanoZolid®-docetaxel study where NanoZolid® combined with docetaxel will be injected into solid tumors. The first injection was administered at...

Pharma R&D 2019 attracted a large number of academic and pharmaceutical industry delegates interested in finding new drug delivery technologies for drug products. LIDDS presented the NanoZolid®...

A collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer. The collaboration has...